Camurus and Lilly have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Nordic stocks gained Wednesday, with the OMX Nordic 40 Index rising 1.3%. Camurus AB was the biggest leader among large stocks during the session, soaring 23.9%, and Thule Group AB gained 5.6%. Sinch ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.

US pharma major Eli Lilly (NYSE: LLY) has struck a deal worth up to $870 million with Swedish biotech Camurus (Nasdaq ...

Eli Lilly recently entered into a technology transfer agreement with Swedish biotech company Camurus. Camurus is transferring long-term treatment technology for cardiovascular and metabolic disease ...